X

Articles

22Apr

Update on CTS Implementation of the Grifols Procleix Ultrio Elite Assay

0 Comments | | Return |

In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV, and HCV), performed on the Tigris testing platform, to the newer Ultrio Elite triplex assay, and performed on the Panther testing platform. The CTS Phoenix lab will implement first on July 7th, with the 4 remaining CTS labs located in Charlotte, Dallas, St. Louis amd Tampa all implementing on July 13, 2020.

 

Click here for all the details: Communications

Related

Seasonal Monitoring for WNV to begin June 1, 2019

Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...

Read More >

CTS Implements HLA Class I and II Testing on the Gemini

CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...

Read More >

National Blood Donor Month

National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...

Read More >

Reminder-Confirmatory Algorithm and Assay Changes Effective September 30, 2019

On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...

Read More >

Reminder-Bio-Rad Geenius HIV 1/2 Implemented

CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...

Read More >

CTS moving to new sFTP Server

CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...

Read More >